Background: ADAM15, also known as Metargidin and MDC15, is a member of the ADAM (a disintegrin and metalloprotease like domain) family. It was first described in mammary epithelial carcinoma cells as a membrane anchored Metalloprotease Disintegrin with RGD sequence (MetaRGiDin). Mouse ADAM15 does not contain the RGD sequence; instead the mouse ADAM15 has a TDD in its place. Like ADAM9 and ADAM12, there are SH3 ligand domains in the cytoplasmic portion of ADAM15, suggesting regulation routes for ADAM15 via Src and Src tyrosine kinase. ADAM15 contains the canonical HExxHxxxxxH zinc metalloproteinase motif, and has been shown to be proteolytically active. Full length ADAM15, 814 amino acids, has a predicted mass of 85 kDa, but due to glycosylation and cysteine rich regions, the reduced protein migrates to 110 kDa (unprocessed) and 84 kDa (processed). ADAM15 is widely expressed in normal tissues and tumor cell lines, and is expressed on the cell surface, anchored by the transmembrane domain. It is also elevated in osteoarthritic and rheumatoid synovial tissues, suggesting an inflammatory role. ADAM15 may also act as a cell attachment molecule by binding the integrins avbeta3 and a5beta1 through the cysteine rich domain and/or RGD sequence.

Description: Rabbit polyclonal to ADAM15

Immunogen: KLH conjugated synthetic peptide derived from ADAM15

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 88 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/100-500;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.